(1)__Broadcast on television or radio from a station that is physically located in the State;

(2)__Broadcast over the Internet from a location in the State;__or

(3) Printed in magazines or newspapers that are printed, distributed or sold in the State.

2. Regulated advertisement requirement.__Beginning October 15, 2005, a manufacturer may not present or cause to be presented in the State a regulated advertisement, unless that advertisement meets the requirements concerning misbranded drugs and devices and prescription drug advertising of federal law and regulations under 21 United States Code, Sections 331 and 352(n) and 21 Code of Federal Regulations, Part 202 and state rules.

3.__Disclosure of clinical trials of prescription drugs.__ Beginning October 15, 2005, a manufacturer or labeler of prescription drugs that is required to report marketing costs for prescription drugs pursuant to section 2698-A shall post, with regard to those prescription drugs, on the publicly accessible Internet website of the federal__National Institutes of Health or its successor agency or another publicly accessible website the following information concerning any clinical trial that the manufacturer conducted or sponsored on or after October 15, 2002:

A. The name of the entity that conducted or is conducting the clinical trial;

B. A summary of the purpose of the clinical trial;

C. The dates during which the trial has taken place; and

D. Information concerning the results of the clinical trial, including potential or actual adverse effects of the drug.

In order to satisfy the requirements of this subsection, the publicly accessible website and manner of posting must be acceptable to the department.

4.__Fees.__ Beginning April 1, 2006, each manufacturer of prescription drugs that are provided to Maine residents through the MaineCare program under section 3174-G or the elderly